Related Experiment Video
Updated: Aug 9, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Nonstructural 5A protein of hepatitis C virus modulates tumor necrosis factor alpha-stimulated nuclear factor kappa B
Kyu-Jin Park1, Soo-Ho Choi, Soo Young Lee
1Institute of Environment and Life Science, The Hallym Academy of Sciences, Hallym University, 1 Ockcheon-dong, Chuncheon 200-702, Korea.
Abstract:
The hepatitis C virus nonstructural protein 5A (NS5A) is a multifunctional phosphoprotein that leads to pleiotropic responses, in part by regulating cell growth and cellular signaling pathways. Here we show that overexpression of NS5A inhibits tumor necrosis factor (TNF)-alpha-induced nuclear factor kappaB (NF-kappaB) activation in HEK293 cells, as determined by luciferase reporter gene expression and by electrophoretic mobility shift assay. When overexpressed, NS5A cannot inhibit the recruitment of TNF receptor-associated factor 2 (TRAF2) and IkappaB kinase (IKK)beta into the TNF receptor 1-TNF receptor-associated death domain complex. In contrast, NS5A is a part of the TNF receptor 1 signaling complex. NF-kappaB activation by TNF receptor-associated death domain and TRAF2 was inhibited by NS5A, whereas MEKK1 and IKKbeta-dependent NF-kappaB activation was not affected, suggesting that NS5A may inhibit NF-kappaB activation signaled by TRAF2. Coimmunoprecipitation and colocalization of NS5A and TRAF2 expressed in vivo provide compelling evidence that NS5A directly interacts with TRAF2. This interaction was mapped to the middle one-third (amino acids 148-301) of NS5A and the TRAF domain of TRAF2. Our findings suggest a possible molecular mechanism that could explain the ability of NS5A to negatively regulate TNF-alpha-induced NF-kappaB activation.
Insights
Hepatitis C virus NS5A protein inhibits tumor necrosis factor-alpha-induced nuclear factor kappaB activation by directly interacting with TRAF2. This interaction blocks signaling pathways, offering insights into viral regulation mechanisms.
Area of Science:
- Virology
- Molecular Biology
- Immunology
Background:
- Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) is crucial for viral replication and modulates host cell processes.
- NS5A is a multifunctional phosphoprotein influencing cell growth and signaling pathways.
- Nuclear factor kappaB (NF-kappaB) is a key transcription factor regulating immune responses and cellular functions.
Purpose of the Study:
- To investigate the role of HCV NS5A in regulating tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB activation.
- To elucidate the molecular mechanism by which NS5A affects TNF-alpha signaling pathways.
Main Methods:
- Overexpression of NS5A in HEK293 cells.
- Luciferase reporter gene assays to measure NF-kappaB activity.
- Electrophoretic mobility shift assays (EMSA).
- Coimmunoprecipitation and colocalization studies to assess protein interactions.
- Mapping of interaction domains between NS5A and TRAF2.
Main Results:
- Overexpression of NS5A significantly inhibited TNF-alpha-induced NF-kappaB activation.
- NS5A did not affect the recruitment of TRAF2 and IKKbeta to the TNF receptor signaling complex.
- NS5A directly interacts with TRAF2, specifically with its TRAF domain.
- The interaction site on NS5A was mapped to amino acids 148-301.
- NS5A inhibited NF-kappaB activation downstream of TNF receptor-associated death domain and TRAF2, but not MEKK1 or IKKbeta.
Conclusions:
- HCV NS5A directly interacts with TRAF2, inhibiting TNF-alpha-induced NF-kappaB activation.
- This interaction represents a potential molecular mechanism for NS5A's negative regulation of inflammatory signaling.
- Understanding this interaction could provide insights into HCV pathogenesis and therapeutic strategies.
Related Concept Videos
Co-activators and Co-repressors
Regulation of Nuclear Protein Sorting
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Hepatitis
Cirrhosis II: Pathophysiology

